GALT Galectin Therapeutics
- 3.060
- +0.220+7.75%
- 3.140
- +0.080+2.61%
Galectin Therapeutics News
Galectin Therapeutics 4Q Loss/Shr 19c >GALT
Galectin Therapeutics 4Q Loss/Shr 19c >GALT
Press Release: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update -- Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the con
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate
Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate
Galectin Therapeutics | 10-Q: Quarterly report
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be at
Galectin Therapeutics(GALT.US) Director Buys US$3,520 in Common Stock
$Galectin Therapeutics(GALT.US)$ Director Zordani Richard A. Jr. purchased 1,000 shares of common stock on Apr 30, 2024 at an average price of $3.52 for a total value of $3,520.Source: Announcement Wh
Galectin Therapeutics(GALT.US) Officer Buys US$3,390 in Common Stock
$Galectin Therapeutics(GALT.US)$ Officer LEWIS JOEL purchased 1,000 shares of common stock on Apr 24, 2024 at an average price of $3.39 for a total value of $3,390.Source: Announcement What is stateme
Galectin Therapeutics(GALT.US) 10% Shareholder Sells US$76,500 in Common Stock
$Galectin Therapeutics(GALT.US)$ 10% Shareholder CZIRR JAMES C sold 25,000 shares of common stock on Apr 22, 23, 2024 at an average price of $3.06 for a total value of $76,500.Source: Announcement(one
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Galectin Therapeutics(GALT.US) Director Buys US$7,450 in Common Stock
$Galectin Therapeutics(GALT.US)$ Director FREEMAN KEVIN D purchased 2,500 shares of common stock on Apr 22, 2024 at an average price of $2.98 for a total value of $7,450.Source: Announcement What is s
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Galectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of Belapectin
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients With Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver
Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical Among Healthcare Movers
Galectin Therapeutics Inc.'s (NASDAQ:GALT) 56% Gain Last Week Benefited Both Retail Investors Who Own 57% as Well as Insiders
Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majori
Buy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stability
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.
Analysis
Price Target
No Data
